Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 1/2018

01-01-2018 | Original Paper

Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy

Authors: Umberto Restelli, Alfredo Alberti, Adriano Lazzarin, Marzia Bonfanti, Carmela Nappi, Davide Croce

Published in: The European Journal of Health Economics | Issue 1/2018

Login to get access

Abstract

The WHO estimates that more than 185 million people are infected with hepatitis C virus (HCV) worldwide. The aim of the study is to assess the incremental cost-effectiveness ratio (ICER) of the use of daclatasvir (DCV) + sofosbuvir (SOF) + ribavirin (RBV) for 12 and 16 weeks vs SOF + RBV for 16 and 24 weeks for the treatment of genotype 3 HCV infected cirrhotic patients from the Italian National Health Service (NHS) perspective. A published cohort-based Markov model was used to perform the analysis estimating the lifetime direct medical costs associated with the management of the pathology and the quality adjusted life years gained by patients. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the results. SOF + RBV for 16 weeks was excluded from the analysis due to the significant lower effectiveness, compared with SOF + RBV for 24 weeks (51% vs 79%). DCV + SOF + RBV would increase QALYs and costs in all the comparisons: the ICERs obtained comparing DCV + SOF + RBV for 12 and 16 weeks with SOF + RBV for 24 weeks (reference scenario) are 38,572 €/QALY and 16,436 €/QALY, respectively, both below the 40,000 €/QALY threshold identified by the Italian Health Economics Association. Sensitivity analyses confirmed the robustness of the results. The use of DCV + SOF + RBV is likely to be cost-effective compared with SOF + RBV (for 24 weeks) for the treatment of cirrhotic patients infected with genotype 3 HCV considering a threshold value of 40,000 €/QALY.
Literature
1.
2.
Lavanchy, D.: Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17(2), 107–115 (2011)CrossRef
3.
Westbrook, R.H., Dusheiko, G.: Natural history of hepatitis C. J. Hepatol. 61(1 Suppl), S58–S68 (2014)CrossRef
4.
Cenci, M., Massi, M., Alderisio, M., De Soccio, G., Recchia, O.: Prevalence of hepatitis C virus (HCV) genotypes and increase of type 4 in central Italy: an update and report of a new method of HCV genotyping. Anticancer Res. 27(2), 1219–1222 (2007)PubMed
5.
Pizzillo, P., Almasio, P.L., Ferraro, D., Craxì, A., Di Stefano, R.: HCV genotypes in Sicily: is there any evidence of a shift? J. Med. Virol. 81(6), 1040–1046 (2009)CrossRef
6.
Liberto, M.C., Marascio, N., Zicca, E., Matera, G.: Epidemiological features and specificities of HCV infection: a hospital-based cohort study in a university medical center of Calabria region. BMC Infect. Dis. 12(Suppl 2), S4 (2012)CrossRef
7.
Ansaldi, F., Bruzzone, B., Salmaso, S., Rota, M.C., Durando, P., Gasparini, R., Icardi, G.: Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J. Med. Virol. 76(3), 327–332 (2005)CrossRef
8.
Nkontchou, G., Ziol, M., Aout, M., Lhabadie, M., Baazia, Y., Mahmoudi, A., Roulot, D., Ganne-Carrie, N., Grando-Lemaire, V., Trinchet, J.C., Gordien, E., Vicaut, E., Baghad, I., Beaugrand, M.: HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat. 18(10), e516–e522 (2011)CrossRef
9.
Bochud, P.Y., Cai, T., Overbeck, K., Bochud, M., Dufour, J.F., Müllhaupt, B., Borovicka, J., Heim, M., Moradpour, D., Cerny, A., Malinverni, R., Francioli, P., Negro, F., Swiss Hepatitis C Cohort Study Group: Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J. Hepatol. 51(4), 655–666 (2009)CrossRef
10.
Majumdar, A., Kitson, M.T., Roberts, S.K.: Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy. Drugs 75(8), 823–834 (2015)CrossRef
11.
Kattakuzhy, S., Levy, R., Rosenthal, E., Tang, L., Wilson, E., Kottilil, S.: Hepatitis C genotype 3 disease. Hepatol. Int. (2016) (Epub ahead of print)
12.
Pol, S., Vallet-Pichard, A., Corouge, M.: Treatment of hepatitis C virus genotype 3-infection. Liver Int. 34(Suppl 1), 18–23 (2014)CrossRef
13.
14.
Dugum, M., O’Shea, R.: Hepatitis C virus: here comes all-oral treatment. Cleve. Clin. J. Med. 81(3), 159–172 (2014)CrossRef
15.
Leroy, V., Angus, P., Bronowicki, J.P., Dore, G.J., Hezode, C., Pianko, S., Pol, S., Stuart, K., Tse, E., McPhee, F., Bhore, R., Jimenez-Exposito, M.J., Thompson, A.J.: Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology. 63(5), 1430–1441 (2016)CrossRef
16.
Foster, G.R., Pianko, S., Brown, A., Forton, D., Nahass, R.G., George, J., Barnes, E., Brainard, D.M., Massetto, B., Lin, M., Han, B., McHutchison, J.G., Subramanian, G.M., Cooper, C., Agarwal, K., BOSON Study Group: Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 149(6), 1462–1470 (2015)CrossRef
17.
McEwan, P., Ward, T., Bennett, H., Kalsekar, A., Webster, S., Brenner, M., Yuan, Y.: Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C. PLoS One 10(1), e0117334 (2015)CrossRef
18.
McEwan, P., Ward, T., Chen, C.J., Lee, M.H., Yang, H.I., Kim, R., L’Italien, G., Yuan, Y.: Estimating the incidence and prevalence of chronic hepatitis C infection in Taiwan using back projection. Value Health Reg. Issues 3, 5–11 (2014)CrossRef
19.
McEwan, P., Kim, R., Yuan, Y.: Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl. Health Econ. Health Policy 11(1), 53–63 (2013)CrossRef
20.
McEwan, P., Ward, T., Yuan, Y., Kim, R., L’italien, G.: The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology 58(1), 54–64 (2013)CrossRef
21.
22.
Fattovich, G., Giustina, G., Degos, F., Tremolada, F., Diodati, G., Almasio, P., Nevens, F., Solinas, A., Mura, D., Brouwer, J.T., Thomas, H., Njapoum, C., Casarin, C., Bonetti, P., Fuschi, P., Basho, J., Tocco, A., Bhalla, A., Galassini, R., Noventa, F., Schalm, S.W., Realdi, G.: Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112(2), 463–472 (1997)CrossRef
23.
Grieve, R., Roberts, J., Wright, M., Sweeting, M., DeAngelis, D., Rosenberg, W., Bassendine, M., Main, J., Thomas, H.: Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 55(9), 1332–1338 (2006)CrossRef
24.
Grieve, R., Roberts, J.: Economic evaluation for hepatitis C. Acta Gastroenterol. Belg. 65, 104–109 (2002)PubMed
25.
Shepherd, J., Jones, J., Hartwell, D., Davidson, P., Price, A., Waugh, N.: Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol. Assess. 11(11), 1–205, iii (2007)
26.
Bennett, W.G., Inoue, Y., Beck, J.R., Wong, J.B., Pauker, S.G., Davis, G.L.: Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann. Intern. Med. 127(10), 855–865 (1997)CrossRef
27.
Martin, N.K., Vickerman, P., Miners, A., Foster, G.R., Hutchinson, S.J., Goldberg, D.J., Hickman, M.: Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 55(1), 49–57 (2012)CrossRef
28.
29.
Official Gazette of the Italian Medicines Agency (AIFA). Ex-factory price net of GVT measures as AIFA determination of 03 Jul 2006 and 27 Sept 2006 (2014)
30.
31.
Mennini, F.S., Marcellusi, A., Andreoni, M., Gasbarrini, A., Salomone, S., Craxì, A.: Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy. Clin. Outcomes Res. 19(6), 303–310 (2014)
32.
Wright, M., Grieve, R., Roberts, J., Main, J., Thomas, H.C., UK Mild Hepatitis C Trial Investigators: Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol. Assess. 10(21), 1–113, iii (2006)CrossRef
33.
Castelnuovo, E., Thompson-Coon, J., Pitt, M., Cramp, M., Siebert, U., Price, A., Stein, K.: The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol. Assess. 10(32), 1–93, iii-iv, ix-xii (2006)CrossRef
34.
Sutton, A.J., Edmunds, W.J., Sweeting, M.J., Gill, O.N.: The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis. J. Viral Hepat. 15(11), 797–808 (2008)PubMed
35.
Italian Health Economics Association (AIES): Proposta di Linee-Guida per la valutazione economica degli interventi sanitari. Politiche Sanitarie 10(2), 91–99 (2009)
36.
Russo, P.: La valutazione farmacoeconomica nel contesto regolatorio italiano. Analisi quali-quantitativa dei dossier di richiesta del prezzo e della rimborsabilità. (Pharmacoeconomic evaluations in the Italian regulatory context: a quali-quantitative analysis of pricing and reimbursement dossiers). Pharmacoecon. Ital. Res. Artic. 10, 59–75 (2008)
37.
European Association for Study of Liver: EASL recommendations on treatment of hepatitis C 2015. J. Hepatol. 63(1), 199–236 (2015)CrossRef
38.
Najafzadeh, M., Andersson, K., Shrank, W.H., Krumme, A.A., Matlin, O.S., Brennan, T., Avorn, J., Choudhry, N.K.: Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann. Intern. Med. 162(6), 407–419 (2015)CrossRef
39.
Moshyk, A., Martel, M.J., Tahami Monfared, A.A., Goeree, R.: Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada. J Med Econ. 11, 1–12 (2015)
40.
McEwan, P., Ward, T., Webster, S., Yuan, Y., Kalsekar, A., Kamae, I., Kobayashi, M., Tang, A., Kumada, H.: Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. Hepatol Res. 46(5), 423–433 (2015)CrossRef
41.
Gimeno-Ballester, V., Mar, J., San, Miguel R.: Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C. Expert Rev. Pharmacoecon. Outcomes Res. 1, 1–10 (2015)
42.
McEwan, P., Bennett, H., Ward, T., Webster, S., Gordon, J., Kalsekar, A., Yuan, Y., Brenner, M.: The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK. Eur. J. Gastroenterol. Hepatol. (2015)
43.
Vargas, C.L., Espinoza, M.A., Giglio, A., Soza, A.: Cost effectiveness of daclatasvir/asunaprevir versus peginterferon/ribavirin and protease inhibitors for the treatment of hepatitis C genotype 1b naïve patients in Chile. PLoS One 10(11), e0141660 (2015)CrossRef
Metadata
Title
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy
Authors
Umberto Restelli
Alfredo Alberti
Adriano Lazzarin
Marzia Bonfanti
Carmela Nappi
Davide Croce
Publication date
01-01-2018
Publisher
Springer Berlin Heidelberg
Published in
The European Journal of Health Economics / Issue 1/2018
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-016-0865-3

Other articles of this Issue 1/2018

The European Journal of Health Economics 1/2018 Go to the issue

Current Opinion

Patient preferences: a Trojan horse for evidence-based medicine?

Original Paper

A “healthy immigrant effect” or a “sick immigrant effect”? Selection and policies matter

Editorial

Competition in pharmaceuticals: more product- than price-oriented?

Original Paper

A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK

Original Paper

Competition and quality indicators in the health care sector: empirical evidence from the Dutch hospital sector

Original Paper

Investigating social inequalities in older adults’ dentition and the role of dental service use in 14 European countries